The AJMC® Product Approvals and Launches page will cover the latest FDA product approvals, as well as product launches in the United States.
5 First-in-Class, First-in-Disease FDA Approvals From August
FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors
Navigating the Alzheimer Disease Blood Test Revolution
Rilzabrutinib Becomes First FDA-Approved BTK Inhibitor for ITP
COVID-19 Vaccine Booster Receives Approval With Limits on Patient Access
Brensocatib Approval Sparks New Questions in Bronchiectasis Research: James D. Chalmers, MBChB, PhD
FDA Expands Evolocumab Label for Adults With Increased MACE Risk From Uncontrolled LDL-C
Brensocatib Approval Highlights Potential of DPP1 Inhibitors for Neutrophil-Mediated Diseases: James D. Chalmers, MBChB, PhD
Brensocatib's Safety Profile Suggests Manageable AEs in Clinical Practice: James D. Chalmers, MBChB, PhD
FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema
Brensocatib Becomes First Approved Therapy for Bronchiectasis, Expanding Treatment Options: James D. Chalmers, MBChB, PhD
FDA Issues CRL for Vatiquinone in Friedreich Ataxia, Requests More Efficacy Data
FDA Approves Zopapogene Imadenovec for Recurrent Respiratory Papillomatosis
TNX-102 SL Now Fourth FDA-Approved Treatment for Fibromyalgia
FDA Approves Semaglutide for MASH With Fibrosis
Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis
Tafasitamab Approval Expands Chemotherapy-Free Treatment Options for R/R Follicular Lymphoma: Christina Poh, MD
5 Hot FDA Approval Dates That Made Waves Across Therapeutic Areas in July
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma
Ensuring Access to Pegcetacoplan Requires Updated Guidelines, Education, and Distribution Solutions: Carla Nester, MD, MSA, FASN
Pegcetacoplan Offers Promising New Treatment Approach for Patients Aged 12 and Older With C3G, Primary IC-MPGN: Carla Nester, MD, MSA, FASN
Linvoseltamab Approval Expands Access, Increases Competition in BCMA Bispecifics Space: Sundar Jagannath, MBBS
Linvoseltamab May Bring Multiple Myeloma Care Closer to Home: Sundar Jagannath, MBBS
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
Linvoseltamab Offers Hope for Patients With Refractory Multiple Myeloma: Sundar Jagannath, MBBS
FDA Approves Delgocitinib for Moderate to Severe Hand Eczema
How Fitusiran Changes the Treatment Landscape in Hemophilia: Guy Young, MD
Practical Considerations, Future Outlook for Linvoseltamab in Multiple Myeloma Care: Hans Lee, MD
Linvoseltamab Approval Offers New Off-the-Shelf Option for Heavily Pretreated Multiple Myeloma: Hans Lee, MD
Concerns Persist Over Reliance on Surrogate End Points in FDA Accelerated Approvals